Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emvistagrast - Gilead Sciences

Next Previous
Drug Profile

Emvistagrast - Gilead Sciences

Alternative Names: GS-1427; α4β7 inhibitor - Gilead Sciences

Latest Information Update: 10 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Anti-inflammatories
  • Mechanism of Action Integrin alpha4beta7 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 04 Mar 2026 Pharmacokinetic and adverse events data in Inflammatory bowel disease presented at 127th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT -2026)
  • 08 Sep 2024 Pharmacokinetics and adverse event data from the phase I trial in Inflammatory bowel diseases presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in Australia (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top